Dermatol. praxi. 2019;13(1):34-44 | DOI: 10.36290/der.2019.020
Humira still has a lot to offer
- I. dermatovenerologická klinika FN u sv. Anny v Brně a LF MU, Brno
Humira has been on the market in the Czech Republic for 20 years in indications such as rheumatoid arthritis, Bechterev's disease or inflammatory bowel disease. For psoriasis treatment, Humira was registered in the Czech Republic in 2008 as one of the first biological preparations in this indication. Recent studies have also shown a very good adalimumab efficacy in specific and resistant forms of psoriasis, such as palmoplantar or nail psoriasis. Its indications have been extended in dermatological (hidradenitis suppurativa) and ophthalmological (uveitis) conditions as well as in some pediatric indications. Recent volume reduction in Humira injections and pens, as well as the removal of citrate, have contributed to the pain reduction and increase of patients' comfort during the administration of treatment. The main atvantage of Humira is its high efficacy and long-term safety, which is supported by recent data from registries, including favorable data on pregnant and breast-feeding women treated with this preparation. In addition, Humira has been able to maintain its high quality in the long term use and its composition has been consistent over time despite increased volume of production, as documented by the long-term monitoring and control of adalimumab molecule stability.
Keywords: Humira, current indications, pharmaceutical forms, safety data
Received: June 19, 2018; Accepted: July 18, 2018; Published: March 21, 2019 Show citation
References
- SPC Humira
- Gordon K et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2): 241-251
Go to original source... 
Go to PubMed... - Saurat JH et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION); CHAMPION Study Investigators.Br J Dermatol. 2008 Mar;158(3): 558-566 Go to original source... Go to PubMed...
- Leonardi C et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. BJD, 658-667.
- Elewski B et al. Adalimumab for nail psoriasis: Efficacy and safety from the first 26 weeks of a phase 3, randomized, placebo-controlled trial. J Am Acad Dermatol. 2018 Jan; 78(1): 90-99. Go to original source... Go to PubMed...
- Gkalpakiotis S et al. Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic. Journal of Dermatological Treatment. Vol 29, 2018, 6, 579-582. Go to original source... Go to PubMed...
- Gordon K et al. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb;66(2):241-51. Go to original source... Go to PubMed...
- Kerdel F et al. Seven-Year Interim Results from the ESPRIT 10-Year Postmarketing Surveillance Registry of Adalimumab for Moderate to Severe Psoriasis. P4848 Presented at the 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL, March 3-7, 2017.
- Burmester G et al. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013;72:517-524. Go to original source... Go to PubMed...
- Burmester G et al. Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years. P2481 Presented at the American College of Rheumatology Annual Meeti ng, November 3-8, 2017, San Diego, California, United States. Go to original source...
- Kimbal AB et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016 Aug 4; 375(5): 422-34. Go to original source... Go to PubMed...
- Zouboulis CC. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019 Jan; 80(1): 60-69. Go to original source... Go to PubMed...
- Slonková V. Možnosti léčby hidradenitis suppurativa. Dermatol. praxi 2017; 11(4): 131-134. Go to original source...
- Nash P. Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. Rheumatol Ther. 2016 Dec; 3(2): 257-270. Go to original source... Go to PubMed...
- Tebbey et al. Consistency of quality attributes for the glycosylated monoclonal antibody Humira(R) (adalimumab). MAbs. 2015; 7(5): 805-811. Go to original source... Go to PubMed...
- Burmester G et al. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis 2017; 76: 414-417. Go to original source... Go to PubMed...
- Matro R et al. Exposure concentrations of infants breastfed by women receiving biologie therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 2018; 155(3): 696-704. Go to original source... Go to PubMed...
- Ďuricová D et al. Vliv expozice anti-TNFa in utero na vývoj imunitního systému exponovaných dětí - kontrolovaná multicentrická studie. Gastroent Hepato 2018, 72(6) 479-485. Go to original source...